Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8047)	12/13/1998 9:36:00 PM
From: Robert S.	Read Replies (2) \| Respond to of 17367

It appears integrity is a foreign concept to you: George, why are people still discussing sepsis when it wasn't an anti-sepsis drug that gave Joe Di a rapid turnaround recently. Why worry about sepsis if you have an antibiotic that destroys bacteria effectively and rapidly? To: StockDoc (6930 ) From: Bluegreen Wednesday, Aug 12 1998 6:41PM ET Reply # of 8047 Doc, Doc, Doc, Sepsis is like Cancer???? I liked how you slipped in gram positive example at this stage of the game. If you are serious about Xoma, how about doing some research on BPI especially rBPI21. You might want to check research also on BPI in regards to gram neg. sepsis. Let us concentrate on GRAM NEG. SEPTICEMIA and also synergy with antibiotics first THEN let us deal with gram positive events shall we? What else at this stage? Well why don't you look at phase II results on Hemo. Trauma trial. Might you turn ARDS into a niche group also?